J&J snags novel autoimmune project, and Momenta
The $6.5bn price – biopharma’s biggest buyout of the year so far – shows how competitive the anti-FcRn space has become.
Important catalysts approach for smaller biotechs
Crucial clinical data are expected in the third quarter for small to mid-sized players including Beigene, Turning Point, Intra-cellular and Immunovant.
Argenx sets a high bar with a novel drug class
A new mechanism for certain autoimmune conditions takes a big step forward with impressive pivotal data on Argenx’s efgartigimod.
Upcoming events – Wave takes on Huntington's and Argenx goes subcutaneous
After a delay Wave will finally see data for its Huntington's disease projects while Argenx's subcutaneous efgartigimod needs to keep the competition at bay.
Horizon looks for a new growth driver
The company plans to make the most of its head start with the Graves’ disease project teprotumumab, which is forecast to become its biggest product.
